149634-41-3Relevant academic research and scientific papers
M-STAGE KINESIN INHIBITOR
-
Page/Page column 73, (2010/11/08)
A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.
THIADIAZOLINE DERIVATIVE
-
Page 47, (2010/02/08)
(wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents -C(-W)R6 or the like; R3 represents a hydrogen atom, -C(=WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
DIORGANOSILICON(IV) COMPLEXES OF FLUORO-IMINES: SYNTHETIC, SPECTROSCOPIC AND BIOLOGICAL ASPECTS
Saxena, Chitra,Singh, R. V.
, p. 17 - 26 (2007/10/02)
The synthetic, spectroscopic and biological studies of some diorganosilicon(IV) complexes derived from fluoroimines having NS and NO donor systems have been undertaken. The fluoroimines were prepared by the condensation of 2-Fluorobenzaldehyde and 1-(2-Fl
